Business · 01/09/2016Updated: 10/17/2026 · 1 min read
FDA Renews Cardiovascular and Renal Drugs Advisory Committee for 2 Years
Summary
The FDA Commissioner has renewed the committee for an additional 2 years, extending its charter until August 27, 2018, in the public interest.